Jounce Therapeutics, Inc. – NASDAQ:JNCE
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Jounce Therapeutics stock price monthly change
+1.62%
month
Jounce Therapeutics stock price quarterly change
+55.37%
quarter
Jounce Therapeutics stock price yearly change
-63.21%
year
Jounce Therapeutics key metrics
Market Cap | 98.95M |
Enterprise value | N/A |
P/E | -1.85 |
EV/Sales | -1.71 |
EV/EBITDA | 2.88 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | -0.04 |
EPS | -0.98 |
Revenue | N/A |
EBITDA | -50.15M |
Income | -50.91M |
Revenue Q/Q | 315384515.38% |
Revenue Y/Y | 204.75% |
Profit margin | -62.1% |
Oper. margin | -63.71% |
Gross margin | 0% |
EBIT margin | -63.71% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeJounce Therapeutics stock price history
Jounce Therapeutics stock forecast
Jounce Therapeutics financial statements
| Mar 2022 | 0 | -37.36M | |
|---|---|---|---|
| Jun 2022 | 0 | -33.51M | |
| Sep 2022 | 0 | -30.99M | |
| Dec 2022 | 82M | 50.95M | 62.15% |
| 2022-08-04 | -0.68 | -0.65 |
|---|---|---|
| 2022-11-10 | -0.64 | -0.6 |
| Mar 2022 | 214671000 | 25.70M | 11.98% |
|---|---|---|---|
| Jun 2022 | 188901000 | 31.17M | 16.5% |
| Sep 2022 | 158081000 | 28.72M | 18.17% |
| Dec 2022 | 212550000 | 29.43M | 13.85% |
| Mar 2022 | -33.16M | -2.36M | 409K |
|---|---|---|---|
| Jun 2022 | -23.40M | 40.70M | 33K |
| Sep 2022 | -31.54M | 30.91M | 0 |
| Dec 2022 | 59.23M | 14.22M | 0 |
Jounce Therapeutics alternative data
| Aug 2023 | 141 |
|---|---|
| Sep 2023 | 141 |
| Oct 2023 | 141 |
| Nov 2023 | 141 |
| Dec 2023 | 141 |
| Jan 2024 | 141 |
| Feb 2024 | 141 |
| Mar 2024 | 141 |
| Apr 2024 | 141 |
| May 2024 | 141 |
| Jun 2024 | 141 |
| Jul 2024 | 141 |
Jounce Therapeutics other data
83.17%
+4.36%
of JNCE is owned by hedge funds
108
-12
41.52M
+1.14M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2023 | 0 | 85085 |
| Mar 2023 | 85987 | 0 |
| Apr 2023 | 0 | 39228 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | MURRAY RICHARD /CA/ director | Common Stock | 39,228 | $1.85 | $72,572 | ||
Purchase | TANG KEVIN C 10 percent owner | Common Stock | 20,286 | $1.02 | $20,651 | ||
Purchase | TANG KEVIN C 10 percent owner | Common Stock | 65,701 | $0.99 | $65,307 | ||
Sale | COLE HUGH M officer: Chief Op.. | Common Stock | 9,182 | $1.12 | $10,284 | ||
Sale | DRAPKIN KIMBERLEE C officer: CFO and Treasurer | Common Stock | 7,781 | $1.12 | $8,715 | ||
Sale | MURRAY RICHARD /CA/ director, officer.. | Common Stock | 24,879 | $1.12 | $27,864 | ||
Sale | TREHU ELIZABETH officer: Chief Medical Officer | Common Stock | 5,126 | $1.12 | $5,741 | ||
Sale | COLE HUGH M officer: Chief Op.. | Common Stock | 7,452 | $1.1 | $8,197 | ||
Sale | DRAPKIN KIMBERLEE C officer: CFO and Treasurer | Common Stock | 6,315 | $1.1 | $6,947 | ||
Sale | MURRAY RICHARD /CA/ director, officer.. | Common Stock | 20,191 | $1.1 | $22,210 |
| Patent |
|---|
Application Filling date: 14 Dec 2021 Issue date: 8 Sep 2022 |
Grant Utility: Antibodies to LILRB2 Filling date: 14 Jul 2020 Issue date: 14 Jun 2022 |
Application Filling date: 10 Mar 2020 Issue date: 5 May 2022 |
Grant Utility: Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonist Filling date: 14 May 2019 Issue date: 5 Apr 2022 |
Application Filling date: 24 Oct 2019 Issue date: 9 Dec 2021 |
Application Filling date: 25 Oct 2019 Issue date: 18 Nov 2021 |
Application Filling date: 18 Oct 2019 Issue date: 18 Nov 2021 |
Application Filling date: 5 Feb 2021 Issue date: 4 Nov 2021 |
Application Filling date: 9 Feb 2021 Issue date: 9 Sep 2021 |
Application Filling date: 16 Sep 2020 Issue date: 10 Jun 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2022 10 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 5 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 7 May 2022 | Q1 2022 Earnings Call Transcript |
| Q3 2021 4 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Richard Murray (1959) Pres, Chief Executive Officer & Director | $884,860 |
| Mr. Hugh M. Cole (1965) Chief Bus. Officer & Head of Corporation Devel. | $641,330 |
Ms. Kimberlee Cobleigh Drapkin CPA, CPA (1968) Chief Financial Officer & Treasurer | $582,390 |
-
When is Jounce Therapeutics's next earnings date?
Unfortunately, Jounce Therapeutics's (JNCE) next earnings date is currently unknown.
-
Does Jounce Therapeutics pay dividends?
No, Jounce Therapeutics does not pay dividends.
-
How much money does Jounce Therapeutics make?
Jounce Therapeutics has a market capitalization of 98.95M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 204.75% to 82M US dollars. Jounce Therapeutics made a loss 50.92M US dollars in net income (profit) last year or -$0.6 on an earnings per share basis.
-
What is Jounce Therapeutics's stock symbol?
Jounce Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "JNCE".
-
What is Jounce Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Jounce Therapeutics?
Shares of Jounce Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Jounce Therapeutics's key executives?
Jounce Therapeutics's management team includes the following people:
- Dr. Richard Murray Pres, Chief Executive Officer & Director(age: 66, pay: $884,860)
- Mr. Hugh M. Cole Chief Bus. Officer & Head of Corporation Devel.(age: 60, pay: $641,330)
- Ms. Kimberlee Cobleigh Drapkin CPA, CPA Chief Financial Officer & Treasurer(age: 57, pay: $582,390)
-
How many employees does Jounce Therapeutics have?
As Jul 2024, Jounce Therapeutics employs 141 workers.
-
When Jounce Therapeutics went public?
Jounce Therapeutics, Inc. is publicly traded company for more then 8 years since IPO on 26 Jan 2017.
-
What is Jounce Therapeutics's official website?
The official website for Jounce Therapeutics is jouncetx.com.
-
Where are Jounce Therapeutics's headquarters?
Jounce Therapeutics is headquartered at 780 Memorial Drive, Cambridge, MA.
-
How can i contact Jounce Therapeutics?
Jounce Therapeutics's mailing address is 780 Memorial Drive, Cambridge, MA and company can be reached via phone at 857 259 3840.
Jounce Therapeutics company profile:
Jounce Therapeutics, Inc.
jouncetx.comExchange:
NASDAQ
Full time employees:
141
Industry:
Biotechnology
Sector:
Healthcare
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
780 Memorial Drive
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001640455
ISIN: US4811161011
CUSIP: 481116101
